Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven cancer of the head and neck cancer~* Stage 3 or 4~* Planned primary or adjuvant chemoradiation therapy~* Willing and able to provide informed consent~* English speaking~Exclusion Criteria:~* Currently on gabapentin~* Prior non-tolerance of gabapentin~* History of seizure disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I Standard of Care (Type: ACTIVE_COMPARATOR): Patients receive standard of care consisting of oral health measures, oral rinsing, miracle mouthwash, nonsteroidal anti-inflammatories, and opioid analgesics. Patients also undergo an education session at the beginning of treatment to review foundations of oral care and pain management.
- Arm II Standard of Care Plus Gabapentin (Type: EXPERIMENTAL): Patients receive standard of care and undergo an education session as in Arm I. Patients also receive gabapentin PO three times a day throughout chemoradiation treatment (approximately 5-7 weeks) and until mucositis resolves and pain subsides.

Based on this trial design, predict the completion outcome and termination type (if applicable).